Director of South African Tuberculosis Vaccine Initiative (SATVI) & Full Member of the Institute of Infectious Disease and Molecular Medicine (IDM), Division of Immunology, Department of Pathology, Faculty of Health Sciences, UCT
SATVI is a world leader in TB vaccine clinical research. Their mission is the development of new and effective vaccination strategies against tuberculosis (TB). They are testing multiple new vaccine candidates in clinical trials; and are involved with projects to address critical clinical, epidemiological, immunological and human genetic questions in TB vaccine development. Activities are within an academic context, and thus include the training of postgraduate students.
The team of over 100 staff consists of specialists in: clinical, epidemiological, human genetic and immunologic science, clinical trials, community liaison, recruitment and follow-up; data management and analysis, disease surveillance, information technology, clinical evaluation and care of participants; facility management, laboratory technology, logistics, research pharmacy management, project management, regulatory affairs, administration, study coordination and training.
Professor Hatherill’s clinical research interests have focused on design, implementation, and analysis of clinical trials of BCG vaccine and novel TB vaccines candidates; diagnostic studies of TB infection and disease in adult and paediatric study populations; and TB therapeutic clinical trials. A major new project will test targeted TB preventive therapy for high-risk persons identified by a novel transcriptomic correlate of risk assay.
Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ*, Hatherill M*; C-040-404 Study Team. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.
Van Der Meeren O*, Hatherill M*, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié M-A, Tameris M, Malahleha M, Innes JC, Hellstrom E, Martinson N, Singh T, Akite EJ, Azam AK, Bollaerts A, Ginsberg AM, TG Evans, Gillard P, Tait DR; TB-018 Study Team. Phase 2b placebo-controlled trial of M72/AS01E candidate vaccine to prevent active tuberculosis in adults. N Engl J Med. 2018 Sep [advance electronic publication]
Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. The Lancet (2016) 387(10035):2312-2322.
Tameris MD*, Hatherill M*, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; the MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; S0140-6736(13)60177-4.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056
South African Tuberculosis Vaccine Initiative
Wernher and Beit South Building
Faculty of Health Sciences
University of Cape Town
Anzio Road, Observatory 7925